Neo Ivy Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Neo Ivy Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,212	Closed	-$156K	–	671
2022 Q1	$156K	Buy	6,212 +3,847	+163%	+$108K	0.14%	245
2021 Q4	$86K	Buy	+2,365	New	+$83K	0.12%	234
2021 Q1	–	Sell	-3,340	Closed	-$207K	–	652
2020 Q4	$207K	Buy	3,340 +3,273	+4,885%	+$187K	0.23%	155
2020 Q3	$3K	Buy	+67	New	+$3.61K	﹤0.01%	439
2020 Q2	–	Sell	-3,647	Closed	-$147K	–	640
2020 Q1	$147K	Buy	+3,647	New	+$155K	0.24%	170

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Neo Ivy Capital Management's CCXI Position: Q2 2022 in Review

Neo Ivy Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 6,212 shares — an estimated $156K sold.

Neo Ivy Capital Management first reported a position in CCXI in Q1 2020 and held it in 5 quarters. The position peaked at $207K in Q4 2020. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

Neo Ivy Capital Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
Neo Ivy Capital Management sold 6,212 ChemoCentryx, Inc. shares in Q2 2022, an estimated $156K.
Neo Ivy Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2020 and held it in 5 quarters.
Neo Ivy Capital Management's ChemoCentryx, Inc. position peaked at $207K in Q4 2020.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Neo Ivy Capital Management's 13F filing for Q2 2022, filed 16 Aug 2022.